The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
27-Jul-15
$40.5 billion
Target:
Allergan Generics
Acquiror:
Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business
03-May-07
$8.5 billion
Target:
IPSCO Inc.
Acquiror:
SSAB Svenskt Stål AB
Acted as lead financial advisor to SSAB Svenskt Stål AB on its acquisition of IPSCO Inc., a leading Canadian producer of energy tubulars and steel plate in North America with an annual steel making capacity of 4.3 million tons
10-Jun-20
$3.9 billion
Target:
Global collaboration agreement with Genmab A/S
Acquiror:
AbbVie, Inc
Advised AbbVie, Inc, an NYSE-listed global biopharmaceutical company, on a broad collaboration with Genmab A/S, a leading Danish-listed biotechnology company, to jointly develop and commercialise three next-generation bispecific antibody programs
21-Dec-12
$3.7 billion
Target:
NewPage Corp.
Advised Stora Enso Oyj, a global paper, packaging and wood products producer headquartered in Helsinki, Finland, in connection with the Chapter 11 proceeding of NewPage, the largest North American coated-paper manufacturer
27-Oct-22
$950 million
Target:
Minnesota Rubber and Plastics
Acquiror:
Trelleborg
Facilitated the sale of KKR’s portfolio company Minnesota Rubber and Plastics, a leading provider of materials science-based elastomer and thermoplastic solutions, to Trelleborg
05-Oct-16
$775 million
Target:
Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.
Acquiror:
Accord Healthcare Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)
03-Feb-09
$717 million
Target:
SAS Group
Acquiror:
Norwegian Government
Advised the Norwegian Government in relation to a capital injection in SAS, the leading airline group in Northern Europe
09-Feb-10
$672 million
Target:
SAS Group
Acquiror:
Norwegian Government
Advised the Norwegian Government on strategic and financial matters in relation to a refinancing including a conditional capital injection in SAS, the leading airline group in Northern Europe
28-Jun-16
$652 million
Target:
US rights to 37 approved and 5 pipeline generic products
Acquiror:
Mayne Pharma Group Limited
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products
21-Jun-16
$586 million
Target:
US rights to a broad portfolio of 18 generic products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Impax Laboratories, Inc.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to a broad portfolio of 18 generic products to Impax Laboratories, Inc.
11-Jun-16
$350 million
Target:
US rights to 8 generic drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Dr. Reddy’s Laboratories
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 8 generic drug products to Dr. Reddy’s Laboratories
01-Jun-21
$280 million
Target:
White Drive Motors & Steering business unit of Danfoss A/S
Acquiror:
Interpump S.p.A.
Advising Danfoss, a global leader in power solutions, heating, cooling and drives, on the carve-out sale of White Drive Motors & Steering, a global producer of orbital motors and hydraulic steering units for mobile applications, to Interpump
21-Sep-10
$234 million
Target:
Taro Pharmaceutical Industries
Acquiror:
Sun Pharmaceutical Industries Ltd.
Advised Sun Pharmaceutical Industries Ltd., the largest Indian pharmaceutical company by market capitalization, on its acquisition of a majority interest in Israeli based Taro Pharmaceutical Industries, a multinational generics pharmaceutical company
26-Feb-18
$224 million
Target:
Crem International
Acquiror:
Welbilt
Advised Welbilt, a leading global provider of commercial foodservice equipment on its acquisition of Crem International, a leading manufacturer of professional coffee machines
11-Jan-21
~$150 million
Target:
Nordic Water
Acquiror:
Sulzer AG
Advising Alder, a Swedish sustainability-focused private equity firm, on the divestment of Nordic Water, a supplier of products for the global water and wastewater treatment market, to Sulzer AG
21-Jan-19
$100 million
Target:
UQM Technologies, Inc.
Acquiror:
Danfoss A/S
Advised Danfoss, a global leader in power solutions, heating, cooling and drives, on its acquisition of UQM Technologies
01-Oct-08
$53 million
Target:
Biotage (Biosystems division)
Acquiror:
Qiagen NV
Advised Biotage AB (OMX: BIOT), a global biotechnology company, on its strategic review resulting in the disposal of its Biosystems division which offers systems for genetic analysis mainly for use in clinical research
16-Jun-16
$40 million
Target:
US rights to 5 generic injectable drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Sagent Pharmaceuticals, Inc.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 5 generic injectable drug products to Sagent Pharmaceuticals, Inc.
17-Dec-19
~$35 million
Target:
Sye business area of Net Insight AB
Acquiror:
Amazon.com, Inc.
Advised Net Insight AB, a global leader in media networks, on the sale of Sye, a market-leading true live “over-the-top” (OTT) technology for low-latency live streaming, to Amazon.com, Inc.
22-Sep-20
$NA
Target:
VX Fiber
Acquiror:
AMP Capital
Advised VX Fiber, an international infrastructure and technology business focused on Fibre-to-the-Home networks, on its sale to the infrastructure fund AMP Capital
24-Nov-16
$NA
Target:
Portfolio of 119 marketed and development pipeline products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Rivopharm SA
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 119 marketed and development pipeline products to Rivopharm SA
23-Nov-16
$NA
Target:
Portfolio of generic marketed products in France from Teva Pharmaceutical Industries Ltd.
Acquiror:
Arrow Generiques SAS
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of generic marketed products in France to Arrow Generiques SAS (a subsidiary of Aurobindo Pharma Limited).
24-Feb-21
Undisclosed
Target:
Resource Optimization Software Business Area of Net Insight
Acquiror:
Xytech Systems Corporation
Advising Net Insight AB, a global leader in media networks, on the divestment of its resource optimization software business area, doing business as “ScheduALL” to Xytech Systems Corporation
06-May-11
$NA
Target:
Aker Solutions (Aker Holding)
Acquiror:
Norwegian Government
Advised the Norwegian Government on strategic and financial matters in relation to its investment in Aker Holding, the largest shareholder of Aker Solutions during the demerger of the company’s EPC activities
11-Nov-21
Undisclosed
Target:
Printing Blankets Business of Trelleborg
Acquiror:
Continental AG
Advised Trelleborg AB (STO: TREL), a global leader in engineered polymer solutions, on the disposal of its operation that develops and manufactures printing blankets in polymer-coated fabrics, to Continental